This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
Genomic Biomarker Testing
PEACE-3 Trial
PROfound Trial
PSMAfore Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
BOND-003 Cohort P
CORE-001 Study
CORE-008
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Daniel D. Joyce, MD, MS
Bladder Cancer
Non-Muscle Invasive Bladder Cancer
Ashish Kamat, MD
Muscle-Invasive Bladder Cancer
Advanced & Metastatic Bladder Cancer (mUC)
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher® Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
mCRPC with Bone Metastasis
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
Testicular, Penile & Rare GU Malignances
Testicular Cancer
Functional Urology
Functional Urology
Alan J. Wein, MD, PhD (hon.)
Urologic Catheters - CAUTI Challenges
Videos
Exclusives
Conferences
Disparities: Social Determinants of Health
Exclusive Collaborations
Health Policy in Urological Diseases
Independent Medical Education
Journal Clubs
Practice Guidelines Reviews
The Prostate Cancer Foundation
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Functional Urology
Men's Health
Pelvic Health
Actionable Clinical Data
Bladder Cancer
NMIBC with CIS: Evidence, Practice & Emerging Research
Risk-Stratified NMIBC Management
Trials in Progress
Prostate Cancer
Localized Prostate Cancer
CLARIFY
ESCAPE
FORT
NRG-GU 0101
RTIRE
High Risk BCR HSPC
ARASTEP
Oligometastatic Prostate Cancer
METANOVA
mHSPC
ARASEC
ASPIRE
MEVPRO-3
mCRPC
ECLIPSE
LEGION-100
MEVPRO-1 & 2
PROMISE
SECuRE
Bladder Cancer
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SNMMI 2026
ASCO 2026
AUA 2026
APCCC 2026
PSMA and Beyond 2026
All Conferences
View All
PCF
UroToday Home
Video Lectures
APCCC 2024 Videos
Comparing PSMA Ligands for Prostate Cancer Imaging - Michael Hofman
Hypofractionation in Prostate Cancer Radiotherapy: Balancing Efficacy and Safety - Neha Vapiwala
Escalation Strategies for Suboptimal PSA Decline in mHSPC - Mary-Ellen Taplin
Testosterone Recovery After ADT: Timing, Predictive Factors, and Clinical Implications - Pierre Blanchard
Radiating the Primary Tumor in Metastatic Hormone-Sensitive Prostate Cancer - Sandy Srinivas
EMBARK Trial: Enzalutamide Monotherapy and Combination Therapy for High-Risk Biochemical Recurrence - Neal Shore
Personalizing Salvage Radiation and Hormone Therapy for Biochemical Recurrence - Daniel Spratt
Prognostic and Predictive Factors in Metastatic Hormone-Sensitive Prostate Cancer - Matthew Smith
Optimizing Lutetium-PSMA Dosing in High-Volume Disease and Special Situations - Louise Emmett
Sequencing Therapies in mCRPC After Progression on Combination Treatment - Ian Davis
Managing Frail Patients with Metastatic Hormone-Sensitive Prostate Cancer - Maria De Santis
Redefining Low-Volume Metastatic Prostate Cancer in the Era of PSMA PET Imaging - Oliver Sartor
Optimal Imaging Standards for Metastatic Castration-Sensitive Prostate Cancer - Michael Morris
The Use of PARP Inhibitors in mCRPC with BRCA1/2 Alterations - Joaquin Mateo
Bone Health in Advanced Prostate Cancer: Findings from the STAMPEDE Trial and Hospital Episode Statistics - Noel Clarke
APCCC 2024: Bridging Clinical Gaps in Prostate Cancer Care - Silke Gillessen
Highlighting APCCC 2024: An International Prostate Cancer Meeting - Silke Gillessen & Aurelius Omlin
Navigating the Future of Prostate Cancer Treatment and Global Access at APCCC 2024 - Silke Gillessen
PSMA PET Imaging Hot Topics - Neal Shore & Jason Efstathiou
A Urologist's Perspective on PSMA-Radioligand Therapy in the Treatment Setting of mCRPC - Neal Shore
Lutetium-617 - Treatment Sequencing Considerations for Metastatic Castration-Resistant Prostate Cancer - Neal Shore
APCCC 2022: First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer - Evan Yu
Cancer Survivorship and PCF - Matthew Smith & Alicia Morgans
Immune Checkpoint B7-H3 - APCCC 2022 - Emmanuel Antonarakis
Optimal Sequencing - Should It Include Radium Given Lutetium? - Joe O'Sullivan
Genomic and Clinical Markers in nmCRPC APCCC 2022 Presentation - Joaquin Mateo
From ADT to Triplet Therapy: Rethinking Treatment Paradigms in Metastatic Hormone Sensitive Prostate Cancer - Matthew Smith & Kim Chi
Emerging Therapies and Therapeutic Targets in Prostate Cancer - Mark Rubin
Ironman Registry: Pioneering Data Collection and Biomarker Analysis in Prostate Cancer Research Daniel George
How Can Treatment Be Individualized By Using Genomic Classifiers? APCCC 2022 Presentation - Felix Feng
Who Needs Early Salvage Radiotherapy and Who Needs Adjuvant Radiotherapy in 2022? - Kosj Yamoah
Incorporating Molecular Testing into Clinical Practice for Prostate Cancer - Elena Castro & Colin Pritchard
Depression, Bone Health and Exercise in Prostate Cancer - Fred Saad, Tomasz Beer & Charles Ryan
De-escalation Treatment Strategies in Metastatic Hormone-Sensitive Prostate Cancer - Bertrand Tombal
When Low-Volume on Conventional Imaging Goes Into High-Volume on Next-Generation Imaging in mHSPC - Karim Fizazi
The Use of PARP Inhibitors in Castrate-Resistant Prostate Cancer - Elena Castro & Joaquin Mateo
PARPi Combination Therapy Use in Clinical Practice - Ready for Prime-Time? - Maha Hussain and Fred Saad
Closing Remarks from the 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) - Silke Gillessen, Aurelius Omlin, Neal Shore, Charles Ryan & Alicia Morgans
Systemic Treatment in the Context of Salvage Radiation and Biochemical Recurrence - Piet Ost
The Conundrum of Systemic Salvage Therapy at the Time of Salvage Radiation Therapy - Brandon Mahal
Demystifying PSMA Theranostics: A Discussion on Implementing Lutetium-177 Treatment - Oliver Sartor
Beyond Clinical Trials: Mastering Patient Care for Lutetium-PSMA-617 Therapy - Michael Morris
Looking Forward to the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 - Aurelius Omlin
The APCCC 2022 - A Hybrid Meeting April 28 - 30 - Silke Gillessen
The APCCC 2021 Focuses on Key Areas of Advanced Prostate Cancer Management: Newly Diagnosed mHSPC, PSMA in Diagnostics and Therapy and Novel Targets in mCRPC - Silke Gillessen
Looking Forward to The Advanced Prostate Cancer Consensus Conference (APCCC) 2021 - Silke Gillessen and Aurelius Omlin
Reflections on Advanced Prostate Cancer Consensus Conference 2019 - Srikala Sridhar
The Side Effects of Advanced Prostate Cancer Consensus Conference 2019 (APCCC) - Silke Gillessen and Aurelius Omlin
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free
